Glycogen Synthase Kinase-3 Beta Expression Correlates With Worse Overall Survival in Non-Small Cell Lung Cancer—A Clinicopathological Series

Background Glycogen Synthase Kinase-3 beta (GSK-3β) regulates diverse cell functions including metabolic activity, signaling and structural proteins. GSK-3β phosphorylates target pro-oncogenes and regulates programmed cell death-ligand 1 (PD-L1). This study investigated the correlation between GSK-3β expression and clinically relevant molecular features of lung adenocarcinoma (PDL1 score, PTEN expression and driver mutations). Methods We evaluated 95 lung cancer specimens from biopsies and surgical resections. Immunohistochemistry was performed to analyze the expression of GSK-3β, PTEN, and PDL1. Epidemiological data, molecular characteristics and staging were evaluated from medical records. The histologic classification was performed by an experienced pulmonary pathologist. Results Most patients were female (52.6%) and the majority had a positive smoking history. The median age was 68.3 years, with individuals over 60 years accounting for 82.1%. The predominant histological subtype was adenocarcinoma (69.5%), followed by squamous cell carcinoma (20.0%). GSK-3β expression in tumors was cytoplasmic with a dotted pattern and perinuclear concentration, with associated membranous staining. Seven (7.3%) tumors had associated nuclear expression localization. Seventy-seven patients (81.1%) had advanced clinical-stage tumors. GSK-3β was positive in 75 tumors (78%) and GSK3-positive tumors tended to be diagnosed at advanced stages. Among stage III/IV tumors, 84% showed GSK3 positivity (p= 0.007). We identified a statistically significant association between GSK-3β and PTEN in the qualitative analysis (p 0.021); and when comparing PTEN to GSK-3β intensity 2+ (p 0.001) or 3+ expression (> 50%) – p 0.013. GSK-3β positive tumors with a high histological score had a worse overall survival. Conclusion We identified the histological patterns of GSK-3β expression and evaluated its potential as marker for overall survival, establishing a simple histological score to measure the evaluated status in resected tissues. The use of GSK-3β expression as an immune response biomarker remains a challenge. Future studies will seek to explain the role of its interaction with PTEN.

[1]  J. McCubrey,et al.  The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment , 2020, Cells.

[2]  P. Munster,et al.  Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. , 2020 .

[3]  Longzhen Zhang,et al.  Increased Expression of T-Box Transcription Factor Protein 21 (TBX21) in Skin Cutaneous Melanoma Predicts Better Prognosis: A Study Based on The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) Databases , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[4]  C. Rudd,et al.  Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity. , 2020, Cell reports.

[5]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  Sulaimon Bakre,et al.  Diffuse alveolar damage and e-cigarettes: Case report and review of literature , 2019, Respiratory medicine case reports.

[7]  N. Said,et al.  PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics , 2019, Cancers.

[8]  A. Rotte,et al.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of Experimental & Clinical Cancer Research.

[9]  B. Carneiro,et al.  Molecular profile of non-small cell lung cancer in northeastern Brazil , 2019, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[10]  Chuan-Ming Xie,et al.  Activation of PTEN by inhibition of TRPV4 suppresses colon cancer development , 2019, Cell Death & Disease.

[11]  Z. Szallasi,et al.  Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma , 2019, Acta oncologica.

[12]  B. Carneiro,et al.  Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses , 2019, Cancer biology & therapy.

[13]  C. Rudd,et al.  Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. , 2019, Seminars in immunology.

[14]  Nicolai J. Birkbak,et al.  Neoantigen-directed immune escape in lung cancer evolution , 2019, Nature.

[15]  N. Leslie,et al.  Mechanisms of PTEN loss in cancer: It's all about diversity. , 2019, Seminars in cancer biology.

[16]  Min Gyu Lee,et al.  PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression , 2019, Nature Communications.

[17]  A. Piotrowska,et al.  Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers , 2019, International journal of molecular sciences.

[18]  Weilin Wang,et al.  Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  L. Xia,et al.  PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions , 2019, The oncologist.

[20]  A. Tafreshi,et al.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Karen J. Liu,et al.  ALK and GSK3: Shared Features of Neuroblastoma and Neural Crest Cells , 2018, Journal of experimental neuroscience.

[23]  A. Ceribelli,et al.  Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC , 2018, AntiCancer Research.

[24]  F. Tanaka,et al.  Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). , 2018, Journal of UOEH.

[25]  N. D. de Miranda,et al.  Cancer immunotherapy: broadening the scope of targetable tumours , 2018, Open Biology.

[26]  Sindeval José da Silva,et al.  Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients , 2018, Virchows Archiv.

[27]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[28]  James E. Muller,et al.  Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal* , 2018, Molecular & Cellular Proteomics.

[29]  Rongsheng Tong,et al.  Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma , 2018, International journal of oncology.

[30]  Nasimul Hoda,et al.  GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future. , 2017, Current pharmaceutical design.

[31]  Dandan Wu,et al.  PTEN Gene Induces Cell Invasion and Migration via Regulating AKT/GSK-3β/β-Catenin Signaling Pathway in Human Gastric Cancer , 2017, Digestive Diseases and Sciences.

[32]  N. Leslie,et al.  GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. , 2017, Advances in biological regulation.

[33]  K. Kiura,et al.  Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset , 2017, Japanese journal of clinical oncology.

[34]  ping wang,et al.  Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer , 2017, Oncotarget.

[35]  Jin-jian Lu,et al.  Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells , 2017, Acta Pharmacologica Sinica.

[36]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[37]  Jun Yao,et al.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.

[38]  C. Rudd,et al.  Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses , 2016, Immunity.

[39]  M. Cañadas-Garre,et al.  PTEN and PI3K/AKT in non-small-cell lung cancer. , 2015, Pharmacogenomics.

[40]  Xin Jin,et al.  Upregulation of cyclooxygenase-2 is associated with activation of the alternative nuclear factor kappa B signaling pathway in colonic adenocarcinoma. , 2015, American journal of translational research.

[41]  Stephen L. Abrams,et al.  Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. , 2015, Advances in biological regulation.

[42]  K. Ikeda,et al.  [Association between GSK3β polymorphisms and the smoking habits in young Japanese]. , 2015, Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology.

[43]  R. Jope,et al.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. , 2015, Pharmacology & therapeutics.

[44]  W. Travis.  The 2015 WHO classification of lung tumors , 2014, Der Pathologe.

[45]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[46]  Weimin Li,et al.  GSK3β Overexpression Indicates Poor Prognosis and Its Inhibition Reduces Cell Proliferation and Survival of Non-Small Cell Lung Cancer Cells , 2014, PloS one.

[47]  Zhengyu He,et al.  Overexpression of PTEN suppresses lipopolysaccharide-induced lung fibroblast proliferation, differentiation and collagen secretion through inhibition of the PI3-K-Akt-GSK3beta pathway , 2014, Cell & Bioscience.

[48]  S. Lam,et al.  Genetic alterations defining NSCLC subtypes and their therapeutic implications. , 2013, Lung cancer.

[49]  K. Ikeda,et al.  [Haplotype analysis of GSK-3beta gene polymorphisms and smoking behavior]. , 2013, Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology.

[50]  A. Nicholson,et al.  Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. , 2013, Archives of pathology & laboratory medicine.

[51]  A. Nicholson,et al.  Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. , 2013, Archives of pathology & laboratory medicine.

[52]  K. Elenitoba-Johnson,et al.  NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis , 2012, Oncogene.

[53]  Hans Clevers,et al.  Wnt Signaling through Inhibition of β-Catenin Degradation in an Intact Axin1 Complex , 2012, Cell.

[54]  P. Dennis,et al.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models , 2011, Nature Reviews Cancer.

[55]  Jae Heun Lee,et al.  PTEN differentially regulates expressions of ICAM-1 and VCAM-1 through PI3K/Akt/GSK-3β/GATA-6 signaling pathways in TNF-α-activated human endothelial cells. , 2010, Atherosclerosis.

[56]  K. Elenitoba-Johnson,et al.  NPM‐ALK signals through glycogen synthase kinase 3β to promote oncogenesis , 2010 .

[57]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[58]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[59]  R. Jope,et al.  Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics , 2007, Neurochemical Research.

[60]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[61]  T. Honjo,et al.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.

[62]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[63]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[64]  W. Merlevede,et al.  ATP x Mg-dependent protein phosphatase from rabbit skeletal muscle. II. Purification of the activating factor and its characterization as a bifunctional protein also displaying synthase kinase activity. , 1980, The Journal of biological chemistry.

[65]  Fumito Ito,et al.  Current Status and Future Directions , 2013 .

[66]  Sang-Woong Lee,et al.  A case report and review of the literature , 2006, Journal of Neuro-Oncology.

[67]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.